Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

Fungal Status and Prognosis in ABPA

A legfontosabb adatok

Ki végzi
Qianfoshan Hospital
Hol
Jinan (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
114 fő, tervezett
Kezdés
2025. júl. 1.
Várható befejezés
2028. dec. 31.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A regiszteradat frissítve
2026. július 8.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults in hospital with allergic bronchopulmonary aspergillosis (ABPA), an allergic lung reaction to the Aspergillus mould. People are grouped by whether fungal tests on their sputum or lung fluid are positive or negative.

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
ABPA diagnosed by the 2024 ISHAM criteria. Patients must be in hospital at a participating centre during the study period.
Korábbi kezelés
No systemic antifungal treatment, or other treatment that could change fungal test results, in the 1 month before joining.
Biomarker vagy leletérték
At least one fungal test on sputum or lung wash fluid (BALF) with a clear positive or negative result. Tests include fungal culture, galactomannan (GM), mNGS or tNGS.

A részvétel fő kizáró okai

  • Another fungal lung infection, such as invasive pulmonary aspergillosis, or another confirmed lung infection
  • Other structural lung disease, such as tuberculosis, lung cancer or lung abscess
  • Severe immune weakness or another major allergic lung disease
  • Missing key data or not able to complete at least 3 months of follow-up
  • Taking part in another interventional trial, or cannot have bronchoscopy or BAL

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • 1.Adult patients (≥18 years old) diagnosed with allergic bronchopulmonary aspergillosis (ABPA) according to the 2024 International Society for Human and Animal Mycology (ISHAM) diagnostic criteria; 2.Patients hospitalized during the study period in participating centers with sputum or bronchoalveolar lavage fluid (BALF) collection performed; 3.At least one mycological test performed on sputum or BALF, including fungal culture, galactomannan (GM) assay, metagenomic next-generation sequencing (mNGS), or targeted next-generation sequencing (tNGS), with clearly interpretable results (positive or negative); 4.Availability of complete and traceable clinical data, including medical history, imaging, laboratory tests, treatment records, and follow-up information, with no critical missing data; 5.Willingness to participate in follow-up and signed informed consent (for prospective participants), with good compliance for follow-up; 6.No systemic antifungal therapy or other interventions that may significantly affect mycological test results within 1 month prior to enrollment

Ki nem vehet részt

  • 1.Coexisting pulmonary fungal infections (e.g., invasive pulmonary aspergillosis) or other confirmed non-fungal pulmonary infections; 2.Presence of other structural lung diseases, such as pulmonary tuberculosis, lung cancer, or lung abscess; 3.Severe immunodeficiency or other significant allergic pulmonary diseases that may confound the diagnosis of ABPA; 4.Absence of sputum or BALF samples, or lack of valid mycological test results. 5.Incomplete key clinical data (e.g., total IgE, Aspergillus-specific IgE/IgG, imaging, or pulmonary function data) or inability to complete at least 3 months of follow-up; 6.Systemic antifungal treatment within 1 month prior to enrollment or participation in another interventional clinical trial; 7.Contraindications to bronchoscopy/BAL procedures or known severe allergy to relevant reagents used in testing

Helyszínek itt: Kína

  • Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, ChinaJinan, KínaContact: Qian Qi, Dr.Résztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This multicenter bidirectional cohort study aims to investigate the clinical characteristics and prognostic outcomes of patients with allergic bronchopulmonary aspergillosis (ABPA) stratified by fungal microbiological status in sputum or bronchoalveolar lavage fluid (BALF).

A teljes eredeti leírásKevesebb

Patients diagnosed with ABPA according to the ISHAM 2024 criteria will be classified into fungal-positive and fungal-negative groups based on results from fungal culture, galactomannan (GM) testing, and metagenomic next-generation sequencing (mNGS) of sputum or BALF samples.

The study will compare baseline clinical features, laboratory findings, radiological characteristics, treatment response, and long-term outcomes, including acute exacerbation rate and time to first exacerbation, between the two groups.

All participants will be followed for up to 12 months with serial clinical and laboratory assessments.

A vizsgálat 2 csoportja

  • Fungal-Positive ABPA

    Patients diagnosed with allergic bronchopulmonary aspergillosis according to ISHAM 2024 criteria who demonstrate at least one positive result in sputum or bronchoalveolar lavage fluid (BALF) fungal testing, including fungal culture, galactomannan (GM) assay, or targeted next-generation sequencing (tNGS) detecting Aspergillus species.

  • Fungal-Negative ABPA

    Patients diagnosed with allergic bronchopulmonary aspergillosis according to ISHAM 2024 criteria with negative results in all fungal tests performed on sputum or bronchoalveolar lavage fluid (BALF), including fungal culture, galactomannan (GM) assay, and targeted next-generation sequencing (tNGS).

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Clinical Characteristics and Prognostic Outcomes of Allergic Bronchopulmonary Aspergillosis Patients Stratified by Fungal Microbiological Status in Sputum or Bronchoalveolar Lavage Fluid: A Multicenter Bidirectional Cohort Study
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. július 8.